Background. Functional diffusion mapping (fDM ) is a cancer imaging technique that uses voxel-wise changes in apparent diffusion coefficients (ADC) to evaluate response to treatment. Despite promising initial results, uncertainty in image registration remains the largest barrier to widespread clinical application. The current study introduces a probabilistic approach to fDM quantification to overcome some of these limitations. M ethods. A total of 143 patients with newly diagnosed glioblastoma who were undergoing standard radiochemotherapy were enrolled in this retrospective study. Traditional and probabilistic fDM s were calculated using ADC maps acquired before and after therapy. Probabilistic fDM s were calculated by applying random, finite translational, and rotational perturbations to both pre-and posttherapy ADC maps, then repeating calculation of fDM s reflecting changes after treatment, resulting in probabilistic fDM s showing the voxel-wise probability of fDM classification. Probabilistic fDM s were then compared with traditional fDM s in their ability to predict progression-free survival (PFS) and overall survival (O S). Results. Probabilistic fDM s applied to patients with newly diagnosed glioblastoma treated with radiochemotherapy demonstrated shortened PFS and O S among patients with a large volume of tumor with decreasing ADC evaluated at the posttreatment time with respect to the baseline scans. Alternatively, patients with a large volume of tumor with increasing ADC evaluated
D iffusion-weighted imaging (DWI) estimates of apparent diffusion coefficient (ADC), a measure of water mobility obtained using magnetic resonance imaging (M RI), are valuable for assessing subvoxel microstructure in tissues. DWI estimates of ADC have been shown to correlate with tumor cellularity 1 -3 and have shown value in the early assessment of cytotoxic therapy in a variety of cancers, showing a significant increase in ADC in tumors after successful treatment 4, 5 because of destruction of cancer cells and other boundaries for water mobility. Alternatively, a decrease in ADC is thought to be associated with an increase in tumor cellularity and is a characteristic of proliferating tumor. Although many factors can confound the correlation of ADC with tumor cellularity (e.g., edema, changes in steroid dose, infection, and cell morphometry), the high sensitivity of ADC to subtle changes in tumor cellularity has made DWI a valuable, complementary M R technique for routine clinical evaluation of cancer therapy.
Functional diffusion mapping (fDM ) is one method in a new class of imaging biomarkers that quantifies the voxel-wise changes in physiological parameters to assess tumor response to therapy. 3,6 -14 By quantifying voxel-wise changes in ADC (DADC) measured in the same patient over time, fDM s do not assume homogeneity in tumors. Thus, fDM s are a powerful tool for evaluating heterogeneous tumors, including malignant gliomas, such as glioblastoma. FDM s have been shown to be useful in monitoring patients with gliomatosis cerebri, 3 predicting response to standard radiochemotherapy in newly diagnosed glioblastoma 6 and predicting response to anti-angiogenic therapy in recurrent glioblastoma. 15, 16 Despite these promising findings, fDM s have not been implemented clinically in part because of challenges regarding reproducibility of image maps and quantitative information. The accuracy of image coregistration among subsequent ADC maps is the primary mechanism for inaccuracies and errors in fDM analysis and interpretation and the reason that fDM results may vary across different institutions and M R scanners. In the current study, we used a probabilistic approach to fDM quantification, in which finite translational and rotational perturbations were performed after linear registration of ADC maps. These probabilistic fDM s (prob-fDM s) were then applied to a large cohort of patients with newly diagnosed glioblastoma treated with standard radiochemotherapy (n ¼ 143) to determine whether probabilistic fDM s were a better predictor of progression-free survival (PFS) and overall survival (O S), compared with traditional fDM s.
M ethods Patients
All patients participating in this study signed institutional review board -approved informed consent to have their information in our neuro-oncology database. A total of 143 patients with histologically confirmed, newly diagnosed GBM with high-quality DWIs before and after initiation of radiochemotherapy (external beam radiation therapy and temozolomide) were included in the current retrospective study. Baseline (postsurgical, pretreatment) scans were obtained 1 week before therapy, and posttreatment scans were obtained 4 -6 weeks after completion of radiochemotherapy. A total of 66 of the 143 patients was eventually treated with bevacizumab, at either the first or second recurrence. N o patients were treated with bevacizumab during the periods used for fDM analysis. The same cohort of patients was analyzed as part of a previous fDM study involving traditional analyses 6 to directly compare probabilistic fDM performance. M ore details regarding specific patient characteristics can be found in this previous study. 
I nitial Affine Registration
All images for each patient were registered to their own pretreatment, postcontrast, T1-weighted image with use of a mutual information algorithm and a 12 degree of freedom transformation using FSL (FM RIB, O xford, UK; http://www.fmrib.ox.ac.uk/fsl/). Fine registration (1 -2 degrees and 1 -2 voxels) was then performed using a Fourier transform-based, 6 degree of freedom, rigid body registration algorithm, 18 followed by visual inspection to ensure adequate alignment. All images were interpolated to the resolution of baseline T1-weighted images with use of trilinear interpolation.
Finite Perturbations
After linear registration, finite perturbation of both baseline (pretreatment) ADC maps and posttreatment ADC maps was performed along 6 degrees of freedom (x,y, and z translation and u, f , and f rotation) with use of a uniform probability density function for both translation and rotation. Specifically, the probability density function for translation was defined as: and the probability density function for rotation was defined as:
O f note, this corresponds to a maximum translation of + 5 mm and a maximum rotation of + 15 degrees.
The maximum translations and rotations were chosen empirically on the basis of the maximum misalignment of ADC maps observed near the lateral ventricles in our patient cohort. Translational perturbations, Dx, Dy, Dz, were defined to a precision of 10 mm, and rotational perturbations, Du, Df , Df , were defined to 0.01 degrees. After application of finite perturbations, voxelwise subtraction was performed between ADC maps acquired after treatment and at baseline (pretreatment).
Regions of I nterest (RO I s)
In the current study, we used volumetric FLAIR RO Is to interpret fDM results, which have previously been used in nonenhancing and enhancing tumors, 3, 7, 9, 10, 19 because tumor infiltration into normal brain parenchyma typically results in an increase in T2-weighted, or FLAIR, abnormal signal, 20 -23 and multiple investigations have suggested that T2 signal abnormalities should be routinely used to visualize the extent of malignant infiltrating tumor. 24 -28 RO Is were calculated by a single investigator and verified by a board-certified neuroradiologist using a semi-automated procedure 29 consisting of (1) manually defining the relative region of tumor occurrence, (2) thresholding the FLAIR images in these regions using an empirical threshold combined with a region-growing algorithm, and (3) manually editing the resulting masks to exclude any obvious postsurgical cystic or necrotic areas. RO Is were drawn on every slice that contained tumor (i.e., 3D RO Is). RO Is were completed using custom scripts in Analysis of Functional N euroImages software (http://afni.nimh. nih.gov/afni).
Traditional and Probabilistic fD M Q uantification
Individual voxels were stratified on the basis of the change in ADC relative to the baseline ADC map. Voxels having an ADC increase [ADC(+ )] or decrease [ADC (2 ) ] beyond a DADC threshold of 0.4 mm 2 /ms 4 , representing the 95% confidence interval for DADC in a mixture of normal appearing gray and white matter, were labeled with red or blue, respectively, in traditional fDM s. For probabilistic fDM s, voxels having an increase or decrease in DADC threshold of 0.4 mm 2 /ms were categorized as such after each perturbation for a total of 1000 finite, random perturbations. The fraction of all perturbations resulting in significant increases or decreases in DADC was retained for further analysis, resulting in probabilistic maps p(ADC[+ ]) and p(ADC [2 ] ). For traditional fDM s, the total relative hypercellular [ADC (2 ) 
The total number of perturbations was chosen on the basis of an examination of a subset of patients using different numbers of perturbations ranging from 10 to 1 million, for which probabilistic fDM s with 1000 perturbations resulted in probabilities similar to those of fDM s created with 1 million perturbations. To gain better insight into the difference between results obtained from probabilistic and traditional fDM s, consider the following example. Probabilistic fDM s classify a group of 10 voxels as decreasing [ADC (2 ) ] but at a probability of only 25% for each voxel (of 1000 perturbations, these voxels were considered to be significantly lower in 250 perturbations). Thus, the volume fraction for probabilistic fDM s is 10 voxels × 25% ¼ 2.5. N ext, consider a grouping of only 3 voxels categorized on traditional fDM s. Although this is a smaller actual volume of fDM -classified tissue, fDM analysis results in a volume fraction of 3 × 100% ¼ 3.0, which is larger than the volume fraction obtained through probabilistic fDM s. As demonstrated by this example, it is not the entire volume extent of fDM -classified tumor that is important in probabilistic fDM s, but rather the combination of volume and the probability of being classified as abnormal. Receiver-O perator Characteristic (RO C) Analysis and Survival Analysis RO C curves defining the sensitivity and specificity for predicting 12-month PFS and 24-month O S were constructed for both traditional and probabilistic fDM s. The area under the RO C curve (AUC) was used to evaluate RO C performance. For survival analysis, both probabilistic and traditional fDM s were stratified by the median volume fraction for traditional fDM s in all patients (. 20% and , 20% of pretreatment FLAIR RO I). Log-rank statistical analysis was used to test the hypothesis that a large probabilistic fDM -classified volume fraction of decreasing ADC (prob-fDM % ADC [2 ] . 20% ) is indicative of a nonresponsive, growing hypercellular tumor and will result in a significantly shorter PFS and O S. Log-rank analysis was also performed to test the hypothesis that a large probabilistic fDM -classified volume fraction of increasing ADC (prob-fDM % ADC[+ ] . 20% ) is indicative of destruction of tumor cells, a favorable response to radiotherapy, resulting in a significantly longer PFS and O S. PFS was defined from the time of diagnosis to radiographic or neurological progression by the treating neurooncologists, as described in a previous publication. 6 To decrease the likelihood of declaring progression in the context of pseudoprogression, the final treatment scan after radiation was considered to be the baseline scan for evaluating tumor progression. If the subsequent scans showed a definite increase in tumor (≥ 25% increase in the sum of enhancing lesions, new enhancing lesion . 1 cm 2 , an unequivocal qualitative increase in non -contrast-enhancing tumor, or unequivocal new area of non -contrast-enhancing tumor), progression was declared at that time. Change in steroid dose was taken into consideration before defining progression. Patients who did not meet these imaging criteria for progression but had significant neurological decline were declared progressed at the time of irreversible decline. Patients who died before evidence of imaging progression were defined as progressed on the date of death. O S was defined from the time of diagnosis until death.
Results
Probabilistic fDM s, quantifying the probability of obtaining fDM classification per voxel during random, finite perturbations, showed a range of regions with significant increasing and decreasing ADCs. As the number of random perturbations increased, an increasing number of voxels within pretreatment FLAIR abnormal regions were subject to fDM classification, albeit often with a lower probability (Fig. 1A and B) . These results suggest that traditional fDM s using only a single registration step may, in fact, introduce misregistration error. Although the spatial extent of classified tumor was larger in probabilistic, compared with traditional fDM s, tumor burden on probabilistic fDM s is dependent on both the probability of classification and the spatial extent of classified voxels. In general, regions of highest probability of increasing and decreasing ADC corresponded well spatially with traditional fDM s (Fig. 1C and D) ; however, probabilistic fDM s appeared to identify regions suspected of subtle tumor growth not identified by traditional fDM s (Fig. 1D) . Q ualitatively, patients with a large volume of tumor with decreasing ADC on probabilistic fDM s after radiochemotherapy, suggestive of an increase in tumor cell density, appeared to be more likely to progress and die sooner ( Fig. 2A -E) . Alternatively, patients with a larger tumor volume exhibiting an increasing ADC appeared to be more likely to progress later and live longer (Fig. 2F -J) .
RO C Analysis
Both probabilistic and traditional fDM s performed modestly on RO C analysis with respect to 12-month PFS and 24-month O S. A high volume fraction of decreasing ADC on probabilistic fDM s, or high prob-fDM % ADC(2 ), was a significant predictor of 12month PFS ( Fig. 3A ; AUC ¼ 0.6624, P ¼ .0041), showing a sensitivity of 71% and a specificity of 69% for predicting short-term progression-free survivors with use of a threshold of prob-fDM % ADC (2 ) . 20% . Similarly, traditional fDM s (% ADC [2 ] ) in FLAIR-abnormal regions were also a significant predictor of 12-month PFS ( Fig. 3A ; AUC ¼ 0.6423, P ¼ .0107).
Probabilistic fDM s were also a significant predictor of 12-month PFS when evaluating the volume fraction of increasing ADC ( Fig. 3B ; AUC ¼ 0.6186, P ¼ .0352), resulting in a 54% sensitivity and 75% specificity for identifying patients with , 12 month PFS with use of a threshold for prob-fDM % ADC(+ ) of 20% . Traditional fDM volume fraction of increasing ADC (% ADC[+ ]) was not a significant predictor of 12-month PFS ( Fig. 3B ; AUC ¼ 0.6046, P ¼ .0631).
Similar to trends with PFS, probabilistic fDM s consistently outperformed traditional fDM s with respect to 24-month O S. The volume fraction of pretreatment FLAIR abnormal tissue with decreasing ADC on traditional fDM s (% ADC [2 ] ) did not predict 24-month O S according to RO C analysis ( Fig. 3C ; AUC ¼ 0.5788, P ¼ .1511); however, the volume fraction of decreasing ADC on probabilistic fDM s was a significant predictor ( Fig. 3C ; AUC ¼ 0.6117, P ¼ .0419), showing 58% sensitivity and 70% specificity for 24-month O S with use of a threshold of 20% . Similarly, the volume fraction of pretreatment FLAIR-abnormal tissue with increasing ADC on traditional fDM s (% ADC[+ ]) was not a significant predictor of 24-month O S ( Fig. 3D ; AUC ¼ 0.5507, P ¼ .3558), whereas probabilistic fDM s could predict 24-month O S with a 56% sensitivity and 69% specificity with use of a threshold of 20% ( Fig. 3D ; AUC ¼ 0.6516, P ¼ .0074).
Survival Analysis
Log-rank analysis applied to Kaplan -M eier data suggested that patients with a probabilistic fDM -classified volume fraction of decreasing ADC in . 20% of pretreatment FLAIR-abnormal regions (prob-fDM % ADC [2 ] . 20% ), indicative of increased tumor cellularity, had a significantly shorter PFS, compared with patients with a lower volume fraction ( Fig. 4A ; log-rank, P , .0001; hazard ratio [H R] ¼ 3.3). M edian PFS among patients with probabilistic fDM -classified % ADC(2 ) . 20% was 239 days, compared with 602 days for patients with % ADC(2 ) , 20% . The same trends were apparent with traditional fDM s ( Fig. 4A ; log-rank, P ¼ .0004; H R ¼ 2.2), although the H R was significantly lower, compared with probabilistic fDM s (95% confidence interval for probabilistic fDM s ¼ 2.7 , H R , 7.3), suggesting that decreasing ADC on probabilistic fDM s may provide better separation of PFS, compared with traditional fDM s, with use of the same criterion. Patients with a probabilistic fDMclassified volume fraction of increasing ADC . 20% (prob-fDM % ADC [+ ] . 20% ), indicative of decreased cell density, had a significantly longer PFS, compared with patients with a lower volume fraction ( Fig. 4B ; log-rank, P , .0001, H R ¼ 2.5). Traditional fDM s using the same RO I and threshold criteria did not show significant separation of patient groups ( Fig. 4B ; log-rank, P ¼ .3366, H R ¼ 1.3). Patients with a volume fraction of pretreatment FLAIR-abnormal tissue with a decreased ADC on probabilistic fDM s . 20% (prob-fDM % ADC [2 ] . 20% ) were more likely to die sooner than patients with a lower volume fraction ( Fig. 4C ; log-rank, P , .0001; H R ¼ 3.8). Similar to trends in PFS, a large volume fraction of decreasing ADC on traditional fDM s was also predictive of shorter O S ( Fig. 4C ; log-rank, P ¼ .0026; H R ¼ 2.13). Patients with a volume fraction of pretreatment FLAIR-abnormal tissue exhibiting an increase in ADC . 20% , suggestive of more tumor destruction, were more likely to live longer when evaluated using probabilistic fDM s ( Fig. 4D ; log-rank, P ¼ .0105, H R ¼ 1.9), but not when evaluated using traditional fDM s ( Fig. 4 ; log-rank, P ¼ .9658, H R ¼ 1.0). 
Discussion
Voxel-based temporal analysis of physiological imaging data constitutes a new class of imaging biomarkers. These biomarkers include fDM s; cell invasion, motility, and proliferation level estimate maps; 30, 31 functional perfusion maps or perfusion parametric response maps; 32 and differential quantitative T2 maps. 33 fDM s constitute the oldest and most tested of these imaging biomarkers, having been extensively validated 3 and showing sensitivity to predict response to a variety of treatments. 6 -12,34,35 The lack of a measure of uncertainty for image registration, however, is a significant limitation for fDM s and one shared among all voxel-based biomarkers. The current study focused on overcoming this limitation by providing a probabilistic approach to estimating misregistration uncertainty.
Probabilistic fDM s applied to pretreatment FLAIR-abnormal regions were predictive of tumor response to radiochemotherapy and followed trends consistent with previous diffusion M R and traditional fDM studies. ADC is expected to increase as tumor cells are destroyed by cytotoxic therapy. 4, 5 Consistent with this theory and previous fDM analyses, 6 results from the current study suggest that a large volume fraction of tumor that exhibits an increase in ADC is characteristic of more favorable PFS and O S. Alternatively, if tumors are not responding to therapy, a decrease in ADC is expected because of increasing tumor cell density. Results from the current and previous studies 6, 12 support this hypothesis, revealing that patients with a large volume fraction of tumor showing a decrease in ADC had a significantly shorter PFS and O S.
Despite similar trends between the 2 techniques, results from the current study show superior performance of probabilistic fDM s, when compared with traditional fDM s, in terms of their ability to predict PFS and O S in patients with newly diagnosed glioblastoma treated with standard radiochemotherapy. In particular, the volume fraction of both increasing and decreasing ADC on probabilistic fDM s had a significantly higher sensitivity and specificity, compared with traditional fDM s, with respect to predicting 12-month PFS and 24-month O S evaluated using RO C analysis. In addition, log-rank analyses clearly showed greater separation between patient cohorts stratified by similar criteria between the 2 techniques, supported by statistically significant differences in H Rs observed between the 2 techniques. Together, these results support the use of a probabilistic approach to analyze voxel-wise changes in physiological parameters through the use of finite registration perturbations.
Study L imitations
The current study used standard, clinically available DWI sequences that may have posed some potential limitations, including lack of mid-range b values for estimation of perfusion-insensitive ADC according to the recommendations of the N ational Cancer Institute 36 along with using a single-shot echoplanar acquisition, which may have resulted in geometric distortions, leading to increased inaccuracies in image registration. Although previous fDM studies have used similar image acquisition strategies, these limitations may have decreased the clinical sensitivity of both traditional and probabilistic fDM s. In addition, studies have suggested that an additional nonlinear registration step may be advantageous for increasing clinical sensitivity; 15 however, the current study did not directly compare with nonlinear fDM s. It is conceivable that nonlinear registration applied before finite, random perturbations may further increase sensitivity to infiltrating tumor. Although relatively difficult to apply in the context of illdefined structures, such as neoplasms, further analysis involving the use of the Dice Coefficient after each perturbation may be beneficial for additional quantitative comparisons between alignment techniques. In addition, changes in ADC attributable to other pathologies are well documented 37 and are a potential confounder; therefore, clinical implementation of fDM s should also involve interpretation from clinicians to rule out contributions from other factors.
Conclusion
Probabilistic fDM s provide a robust alternative to the use of traditional fDM s with respect both to visualization and to quantification of patient response to treatment. Probabilistic fDM s allow for a relatively registration-independent estimate of fDM parameters, using the sum of all probabilities of fDM classification after random perturbations as a new measure of tumor burden. Probabilistic fDM s are a better prognostic biomarker than traditional fDM s. Future studies aimed at examining the histological features of regions identified as suspected subtle tumor growth on probabilistic fDM s are warranted.
